Ornithyl amphotericin methyl ester treatment of experimental candidiasis in rats

Area of Science:

• Mycology
• Pharmacology
• Infectious Diseases

Background:

• Candida albicans is a common fungal pathogen causing invasive infections.
• Amphotericin B is a widely used antifungal drug but can have significant toxicity.
• Developing safer and more effective antifungal agents is crucial.

Purpose of the Study:

• To compare the efficacy of orinthyl amphotericin methyl ester and amphotericin B in a rat model of intravenous Candida albicans infection.
• To evaluate the dose-dependent effects of these antifungal agents on survival rates.

Main Methods:

• Rats were intravenously infected with Candida albicans.
• Treatment groups received intravenous orinthyl amphotericin methyl ester, amphotericin B, or a diluent (placebo).
• Animals were treated at varying doses (0.1, 0.5, and 2.0 mg/kg) and survival was monitored.

Main Results:

• At lower doses (0.1 and 0.5 mg/kg), both orinthyl amphotericin methyl ester and amphotericin B showed comparable protective effects against mortality.
• At a higher dose (2.0 mg/kg), amphotericin B treatment resulted in increased mortality compared to the placebo group.
• Conversely, orinthyl amphotericin methyl ester at 2.0 mg/kg provided complete protection, preventing all deaths.

Conclusions:

• Orinthyl amphotericin methyl ester exhibits a favorable safety and efficacy profile compared to amphotericin B, particularly at higher therapeutic doses.
• This study suggests orinthyl amphotericin methyl ester may be a more effective and potentially safer alternative for treating severe candidiasis.